Anúncio
Anúncio

RNAC

RNAC logo

Cartesian Therapeutics, Inc. Common Stock

8.20
USD
Patrocinado
+0.07
+0.83%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pré-Mercado

8.38

+0.18
+2.20%

Relatórios de Lucros RNAC

Rácio de surpresa positiva

RNAC separação 18 de 38 últimas estimativas.

47%

Próximo Relatório

Data do Próximo Relatório
11 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$96.56K
/
-$0.87
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-78.64%
/
-36.96%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+25.41%
/
+47.46%

Cartesian Therapeutics, Inc. Common Stock earnings per share and revenue

On 06 de nov. de 2025, RNAC reported earnings of -1.38 USD per share (EPS) for Q3 25, missing the estimate of -0.86 USD, resulting in a -60.11% surprise. Revenue reached 452.00 mil, compared to an expected 248.37 mil, with a 81.99% difference. The market reacted with a -1.56% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.87 USD, with revenue projected to reach 96.56 mil USD, implying an diminuir of -36.96% EPS, and diminuir of -78.64% in Revenue from the last quarter.
FAQ
For Q3 2025, Cartesian Therapeutics, Inc. Common Stock reported EPS of -$1.38, missing estimates by -60.11%, and revenue of $452.00K, 81.99% above expectations.
The stock price moved down -1.56%, changed from $7.67 before the earnings release to $7.55 the day after.
The next earning report is scheduled for 11 de mar. de 2026.
Based on 10 analistas, Cartesian Therapeutics, Inc. Common Stock is expected to report EPS of -$0.87 and revenue of $96.56K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio